ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Researchers in Ireland identify the reason COVID-19 patients develop blood clots
June 18, 2021The blood of COVID-19 patients had higher levels of the pro-clotting VWF molecules and lower levels of the anti-clotting ADAMTS13. -
Researchers identify why Covid-19 patients develop life-threatening clots
June 16, 2021Scientists have identified how and why some Covid-19 patients can develop life-threatening clots, which could lead to targeted therapies that prevent this from happening. -
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Adult Prophylactic Use of VONVENDI [von Willebrand factor (Recombinant)]
June 15, 2021Takeda Pharmaceutical Company Limited announced today that FDA has accepted for review the sBLA) for VONVENDI® [von Willebrand factor (Recombinant)] for prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults.
Pharma Sources Insight January 2025
